✦ LIBER ✦

P-309 Aberrant methylation of the tumor necrosis factor related apoptosis inducing ligand decoy receptor genes in malignant mesothelioma and lung cancer

✍ Scribed by Toyooka, Shinichi; Shivapurkar, Narayan; Toyooka, Kiyomi O.; Miyajima, Kuniharu; Suzuki, Makoto; Redd, Jyotsna; Pass, Harvey I.; Roth, Jack A.; Minna, John D.; Gazdar, Adi F.

Book ID: 118572009
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 168 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92277-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of tumor necrosis factor-relate

The role of tumor necrosis factor-related apoptosis-inducing ligand, death receptor 4 and decoy receptor 1 during follicle development in polycystic ovary syndrome rats

✍ J. Zhang; G. Zhu; X. Wang; L. Hu; B. Xu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Role and prognostic significance of tumo

Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions

✍ Wendy A. Cooper; Maija R.J. Kohonen-Corish; Liqing Zhuang; Brian McCaughan; Cath 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 1 views

## Abstract ## BACKGROUND. The tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) death receptor, DR5, mediates proapoptotic signals and is implicated in the pathogenesis of many neoplasms including nonsmall‐cell lung cancer (NSCLC). ## METHODS. In this study, immunohistochemical ex

Phase II Trial of Mapatumumab, a Fully H

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

✍ von Pawel, Joachim; Harvey, Jimmie H.; Spigel, David R.; Dediu, Mircea; Reck, Ma 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 569 KB

Drug interactions between the proteasome

Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) in prostate cancer: An J, Sun Y-P, Adams J, Fisher M, Belldegrun A, Rettig MB, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA [J An, Y-PS, MF, MBR]; Millennium Pharmaceuticals, Inc., Cambridge, MA [J Adams]; and University of California at Los Angeles School of Medicine, Los Angeles, CA [AB, MBR]. Clinical Cancer Research 2003;9:4537–4545

✍ Gurkamal Chatta 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 18 KB